Zacks Research Research Analysts Lift Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at Zacks Research increased their Q2 2025 earnings estimates for Apellis Pharmaceuticals in a research note issued on Tuesday, April 23rd. Zacks Research analyst R. Department now forecasts that the company will earn $0.23 per share for the quarter, up from their previous estimate of $0.18. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at $0.45 EPS, Q1 2026 earnings at $1.14 EPS and FY2026 earnings at $3.59 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The business had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. During the same period in the prior year, the company posted ($1.50) earnings per share. Apellis Pharmaceuticals’s revenue was up 545.9% compared to the same quarter last year.

Several other research firms also recently commented on APLS. Needham & Company LLC restated a “buy” rating and issued a $85.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, April 9th. HC Wainwright reiterated a “buy” rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, April 15th. Robert W. Baird reiterated an “outperform” rating and set a $81.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. The Goldman Sachs Group increased their price objective on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, January 9th. Finally, Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the stock from $68.00 to $80.00 in a research note on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $77.93.

Apellis Pharmaceuticals Trading Up 2.5 %

APLS stock opened at $49.93 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. The company’s 50-day simple moving average is $58.96 and its 200 day simple moving average is $57.42. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75. The company has a market capitalization of $6.02 billion, a PE ratio of -11.04 and a beta of 0.88.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. raised its holdings in Apellis Pharmaceuticals by 69.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after purchasing an additional 265 shares during the last quarter. Future Financial Wealth Managment LLC bought a new position in Apellis Pharmaceuticals during the 1st quarter worth approximately $29,000. Covestor Ltd raised its holdings in Apellis Pharmaceuticals by 564.2% during the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after purchasing an additional 677 shares during the last quarter. Stephens Consulting LLC bought a new position in Apellis Pharmaceuticals during the 3rd quarter worth approximately $38,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Apellis Pharmaceuticals by 29.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock worth $115,000 after purchasing an additional 687 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 781 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $52,928.37. Following the completion of the transaction, the general counsel now owns 103,390 shares in the company, valued at approximately $7,006,740.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel David O. Watson sold 781 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $52,928.37. Following the completion of the transaction, the general counsel now owns 103,390 shares of the company’s stock, valued at approximately $7,006,740.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 381,011 shares of company stock valued at $23,463,657. 7.50% of the stock is currently owned by insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).